Following its Scorpion Capital controversy in March, Harmony Biosciences is seeking to deepen its pipeline with an acquisition of Zynerba Pharmaceuticals’ cannabinoid therapies for neuropsychiatric disorders.
Tag Archive for: Fragile X syndrome
The company delayed the timeline for reporting key data from a trial of its cannabis-based drug to treat a rare genetic disorder, citing difficulties in enrolling patients amid a rise in respiratory illnesses.
